Table 2 Affected coronary artery status, treatment strategy, and pharmacological therapy at discharge
|  | Survivor group (n = 189) | Cardiac death group (n = 9) | p -value* |
|---|---|---|---|
Number of diseased vessel | NS | ||
 One, n (%) | 80 (42.3) | 2 (22.2) |  |
 Two, n (%) | 54 (28.6) | 3 (33.3) |  |
 Three, n (%) | 55 (29.1) | 4 (44.5) |  |
Stenosis of LMT, n (%) | 15 (7.9) | 2 (22.2) | NS |
Multi-vessel, n (%) | 112 (59.3) | 8 (88.9) | NS |
Target lesion | NS | ||
 LAD, n (%) | 97 (51.3) | 4 (44.5) |  |
 LCX, n (%) | 32 (16.9) | 0 (0.0) |  |
 RCA, n (%) | 53 (28.1) | 3 (33.3) |  |
 LMT, n (%) | 7 (3.7) | 2 (22.2) |  |
Treatment strategy | NS | ||
 PCI (BMS), n (%) | 82 (43.4) | 4 (44.5) |  |
 PCI (DES), n (%) | 64 (33.9) | 3 (33.3) |  |
 POBA, n (%) | 14 (7.4) | 0 (0.0) |  |
 CABG, n (%) | 12 (6.3) | 1 (11.1) |  |
Pharmacological therapy at discharge | |||
Diuretics, n (%) | 39 (20.6) | 5 (55.6) | 0.03 |
Anti-platelets, n (%) | 188 (99.5) | 9 (100) | NS |
Anti-coagulants, n (%) | 15 (7.9) | 2 (22.2) | NS |
CE inhibitor or ARB, n (%) | 134 (70.9) | 7 (77.8) | NS |
Beta-blocker, n (%) | 133 (70.4) | 6 (66.7) | NS |
Calcium-channel blocker, n (%) | 52 (27.5) | 1 (11.1) | NS |
Statin, n (%) | 171 (90.5) | 6 (66.7) | NS |
Oral hypoglycemic agents, n (%) | 20 (10.6) | 2 (22.2) | NS |
 Sulfonylurea, n (%) | 5 (2.7) | 1 (11.1) | NS |
 Alpha-glucosidase inhibitor, n (%) | 9 (4.8) | 0 (0.0) | NS |
 DPP-4 inhibitor, n (%) | 8 (4.2) | 2 (22.2) | NS |
  Metformin, n (%) | 4 (2.1) | 0 (0.0) | NS |
 Pioglitazone, n (%) | 6 (3.2) | 0 (0.0) | NS |
 Glinide, n (%) | 0 (0.0) | 0 (0.0) | NS |
Insulin, n (%) | 2 (1.1) | 0 (0.0) | NS |
Inotropic agents, n (%) | 4 (2.1) | 0 (0.0) | NS |